LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 344

Search options

  1. Article ; Online: Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.

    Lim, Sun Min / Lee, Jii Bum / Cho, Byoung Chul

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2023  Volume 19, Issue 3, Page(s) 376–379

    MeSH term(s) Humans ; Lung Neoplasms/drug therapy ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Pyrimidines/therapeutic use ; Aniline Compounds/pharmacology ; Aniline Compounds/therapeutic use ; ErbB Receptors/genetics ; ErbB Receptors/therapeutic use ; Mutation ; Protein Kinase Inhibitors/therapeutic use ; Acrylamides ; Indoles
    Chemical Substances osimertinib (3C06JJ0Z2O) ; Pyrimidines ; Aniline Compounds ; ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors ; EGFR protein, human (EC 2.7.10.1) ; Acrylamides ; Indoles
    Language English
    Publishing date 2023-11-22
    Publishing country United States
    Document type Editorial
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2023.12.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Durvalumab in combination with chemoradiotherapy in patients with head and neck squamous cell carcinoma: Results from the Phase 1 CLOVER study.

    Bauman, Julie E / Karam, Sana D / O'Brien, Cathy / Mak, Gabriel / Cho, Byoung Chul

    Head & neck

    2024  Volume 46, Issue 5, Page(s) 1152–1159

    Abstract: Background: The Phase 1 CLOVER study (NCT03509012) assessed durvalumab in combination with concurrent chemoradiotherapy (cCRT) in patients with advanced solid tumors; we report results from the head and neck squamous cell carcinoma (HNSCC) cohort.: ... ...

    Abstract Background: The Phase 1 CLOVER study (NCT03509012) assessed durvalumab in combination with concurrent chemoradiotherapy (cCRT) in patients with advanced solid tumors; we report results from the head and neck squamous cell carcinoma (HNSCC) cohort.
    Methods: Patients with histologically/cytologically confirmed locally advanced HNSCC, eligible for definitive cCRT and not considered for primary surgery, received durvalumab plus cisplatin and concurrent external beam radiation. Objectives were to assess safety/tolerability and preliminary efficacy.
    Results: Eight patients were enrolled. The most frequent any-cause adverse events (AEs) were nausea and radiation skin injury (each n = 5); most frequent grade 3/4 AEs were lymphopenia and stomatitis (each n = 3). No patients had dose-limiting toxicities. Objective response rate was 71.4% (5/7 patients; four complete responses, one partial response); disease control rate was 85.7% at 18 weeks and 83.3% at 48 weeks.
    Conclusions: Durvalumab plus cCRT was tolerable and active in patients with unresected, locally advanced HNSCC.
    MeSH term(s) Humans ; Squamous Cell Carcinoma of Head and Neck/therapy ; Squamous Cell Carcinoma of Head and Neck/etiology ; Head and Neck Neoplasms/therapy ; Head and Neck Neoplasms/etiology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemoradiotherapy/adverse effects ; Chemoradiotherapy/methods ; Antibodies, Monoclonal
    Chemical Substances durvalumab (28X28X9OKV) ; Antibodies, Monoclonal
    Language English
    Publishing date 2024-03-17
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article
    ZDB-ID 645165-2
    ISSN 1097-0347 ; 0148-6403 ; 1043-3074
    ISSN (online) 1097-0347
    ISSN 0148-6403 ; 1043-3074
    DOI 10.1002/hed.27726
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1493: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guide.

    Joo, Min Soo / Pyo, Kyoung-Ho / Chung, Jong-Moon / Cho, Byoung Chul

    Frontiers in bioengineering and biotechnology

    2023  Volume 11, Page(s) 1081950

    Abstract: The incidence and mortality rates of lung cancer are high worldwide, where non-small cell lung cancer (NSCLC) accounts for more than 85% of lung cancer cases. Recent non-small cell lung cancer research has been focused on analyzing patient prognosis ... ...

    Abstract The incidence and mortality rates of lung cancer are high worldwide, where non-small cell lung cancer (NSCLC) accounts for more than 85% of lung cancer cases. Recent non-small cell lung cancer research has been focused on analyzing patient prognosis after surgery and identifying mechanisms in connection with clinical cohort and ribonucleic acid (RNA) sequencing data, including single-cell ribonucleic acid (scRNA) sequencing data. This paper investigates statistical techniques and artificial intelligence (AI) based non-small cell lung cancer transcriptome data analysis methods divided into target and analysis technology groups. The methodologies of transcriptome data were schematically categorized so researchers can easily match analysis methods according to their goals. The most widely known and frequently utilized transcriptome analysis goal is to find essential biomarkers and classify carcinomas and cluster NSCLC subtypes. Transcriptome analysis methods are divided into three major categories: Statistical analysis, machine learning, and deep learning. Specific models and ensemble techniques typically used in NSCLC analysis are summarized in this paper, with the intent to lay a foundation for advanced research by converging and linking the various analysis methods available.
    Language English
    Publishing date 2023-02-15
    Publishing country Switzerland
    Document type Systematic Review
    ZDB-ID 2719493-0
    ISSN 2296-4185
    ISSN 2296-4185
    DOI 10.3389/fbioe.2023.1081950
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With

    Nam, Sangho / Lim, Sun Min / Cho, Byoung Chul / Lee, Jii Bum

    JTO clinical and research reports

    2023  Volume 5, Issue 2, Page(s) 100628

    Abstract: Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC ... ...

    Abstract Trastuzumab deruxtecan, an antibody-drug conjugate targetingHER2-expressing tumor cells, was found to have promising results in treatment-refractory, metastatic NSCLC harboring
    Language English
    Publishing date 2023-12-26
    Publishing country United States
    Document type Case Reports
    ISSN 2666-3643
    ISSN (online) 2666-3643
    DOI 10.1016/j.jtocrr.2023.100628
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer.

    Lim, Sun Min / Kim, Chang Gon / Cho, Byoung Chul

    Cancer research

    2022  Volume 82, Issue 1, Page(s) 18–20

    Abstract: The emergence of treatment resistance to targeted agents is currently inevitable and inherently heterogeneous in cancer, presenting significant challenges for improving survival outcomes in patients. This is not an exception for cancers ... ...

    Abstract The emergence of treatment resistance to targeted agents is currently inevitable and inherently heterogeneous in cancer, presenting significant challenges for improving survival outcomes in patients. This is not an exception for cancers harboring
    MeSH term(s) Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; ErbB Receptors/genetics ; Humans ; Immunoconjugates ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Mutation/drug effects ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use
    Chemical Substances Immunoconjugates ; Protein Kinase Inhibitors ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1)
    Language English
    Publishing date 2022-01-04
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 1432-1
    ISSN 1538-7445 ; 0008-5472
    ISSN (online) 1538-7445
    ISSN 0008-5472
    DOI 10.1158/0008-5472.CAN-21-3481
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.135/5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Lazertinib: on the Way to Its Throne.

    Lee, Jiyun / Hong, Min Hee / Cho, Byoung Chul

    Yonsei medical journal

    2022  Volume 63, Issue 9, Page(s) 799–805

    Abstract: Lazertinib is an oral, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that forms an irreversible covalent bond to the Cys797 residue in the ATP-binding site of the EGFR kinase domain and exhibits a ... ...

    Abstract Lazertinib is an oral, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that forms an irreversible covalent bond to the Cys797 residue in the ATP-binding site of the EGFR kinase domain and exhibits a high selectivity for sensitizing and T790M EGFR mutations. In January 2021, it was first approved for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR T790M who had previously received EGFR TKI therapy based on LASER201, a phase I/II trial. At a recommended dose of 240 mg, lazertinib achieved an encouraging anti-tumor activity in both extra- and intracranial lesions. With a high half-maximal inhibitory concentration for EGFR wildtype tumors, it is anticipated to pose a lower risk of skin and cardiac adverse events compared to osimertinib. Lazertinib is currently being investigated as a monotherapy in first-line treatment and in combination with amivantamab under various settings. In this review, we systematically summarize the preclinical and clinical data of lazertinib and discuss future perspectives on the treatment of EGFR-mutant NSCLC.
    MeSH term(s) Antibodies, Bispecific ; Carcinoma, Non-Small-Cell Lung ; ErbB Receptors ; Humans ; Lung Neoplasms ; Morpholines ; Mutation ; Protein Kinase Inhibitors ; Pyrazoles ; Pyrimidines
    Chemical Substances Antibodies, Bispecific ; Morpholines ; Protein Kinase Inhibitors ; Pyrazoles ; Pyrimidines ; amivantamab-vmjw ; lazertinib (4A2Y23XK11) ; ErbB Receptors (EC 2.7.10.1)
    Language English
    Publishing date 2022-08-18
    Publishing country Korea (South)
    Document type Journal Article ; Review
    ZDB-ID 303740-x
    ISSN 1976-2437 ; 0513-5796
    ISSN (online) 1976-2437
    ISSN 0513-5796
    DOI 10.3349/ymj.2022.63.9.799
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 944: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.

    Lim, Sun Min / Kim, Chang Gon / Lee, Jii Bum / Cho, Byoung Chul

    Cancer discovery

    2022  Volume 12, Issue 1, Page(s) 16–19

    Abstract: HER3 is ubiquitously expressed ... ...

    Abstract HER3 is ubiquitously expressed in
    MeSH term(s) Antibodies, Monoclonal, Humanized ; Camptothecin/analogs & derivatives ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; ErbB Receptors/genetics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Protein Kinase Inhibitors/therapeutic use
    Chemical Substances Antibodies, Monoclonal, Humanized ; Protein Kinase Inhibitors ; patritumab deruxtecan (3XPI7EG4W8) ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1) ; Camptothecin (XT3Z54Z28A)
    Language English
    Publishing date 2022-02-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-21-1429
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6916: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?

    Kim, Chang Gon / Cho, Byoung Chul / Lim, Sun Min

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2021  Volume 16, Issue 5, Page(s) 709–711

    MeSH term(s) Benzamides ; Humans ; Imidazoles ; Lung Neoplasms/drug therapy ; Protein Kinase Inhibitors/therapeutic use ; Triazines
    Chemical Substances Benzamides ; Imidazoles ; Protein Kinase Inhibitors ; Triazines ; capmatinib (TY34L4F9OZ)
    Language English
    Publishing date 2021-03-31
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2021.02.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer.

    Choi, Su-Jin / Lee, Jii Bum / Kim, Jae Hwan / Hong, Min Hee / Cho, Byoung Chul / Lim, Sun Min

    Therapeutic advances in medical oncology

    2024  Volume 16, Page(s) 17588359241240657

    Abstract: Background: Identifying actionable driver mutations : Methods: All surgically resected NSCLC samples (: Results: Stage distribution post-surgery was 80% I (: Conclusion: TSO500 and F1CDx showed robust analytical performance for TMB assessment ... ...

    Abstract Background: Identifying actionable driver mutations
    Methods: All surgically resected NSCLC samples (
    Results: Stage distribution post-surgery was 80% I (
    Conclusion: TSO500 and F1CDx showed robust analytical performance for TMB assessment with TSO500 showing stronger concordance of TMB with high PD-L1 expression. As the paradigm for the management of early-resected NSCLC continues to evolve, understanding TMB and the mutation landscape may help advance clinical outcomes for this subset of patients.
    Language English
    Publishing date 2024-03-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 2503443-1
    ISSN 1758-8359 ; 1758-8340
    ISSN (online) 1758-8359
    ISSN 1758-8340
    DOI 10.1177/17588359241240657
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Advances in the management of non-small-cell lung cancer harbouring

    Low, Jia Li / Lim, Sun Min / Lee, Jii Bum / Cho, Byoung Chul / Soo, Ross A

    Therapeutic advances in medical oncology

    2023  Volume 15, Page(s) 17588359221146131

    Abstract: Epidermal growth factor receptor ( ...

    Abstract Epidermal growth factor receptor (
    Language English
    Publishing date 2023-01-27
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2503443-1
    ISSN 1758-8359 ; 1758-8340
    ISSN (online) 1758-8359
    ISSN 1758-8340
    DOI 10.1177/17588359221146131
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top